SEOUL, South Korea, July 27, 2026
Seegene Inc., a global leader in molecular diagnostics, has announced a comprehensive Syndromic PCR-based testing strategy for reproductive tract infections (RTIs) through its Global Million Clinical Study (GMCS). The initiative seeks to establish a new global standard for PCR diagnostics by evaluating the clinical value of simultaneously detecting human papillomavirus (HPV) and sexually transmitted infection (STI) pathogens using real-world clinical evidence. Leveraging its STAgora™ real-time analytics platform, Seegene analyzed approximately 60,000 HPV and STI co-testing results collected over 42 months, revealing that 82% of HPV-positive patients also tested positive for at least one STI pathogen. These findings support the growing scientific rationale for comprehensive molecular testing that can provide clinicians with broader diagnostic information from a single patient sample while improving disease detection, patient management, and reproductive healthcare outcomes.
Large-Scale Clinical Analysis Supports Comprehensive HPV and STI Testing
Seegene’s analysis of approximately 60,000 clinical test results using its proprietary STAgora™ analytics platform demonstrated significant overlap between HPV infections and sexually transmitted infections. According to the company’s findings, STI pathogens were identified in 82% of HPV-positive cases, while 46% of STI-positive patients were also positive for HPV. Furthermore, 71% of all positive results obtained through comprehensive testing involved simultaneous detection of both HPV and STI pathogens. These results highlight the potential clinical value of performing concurrent HPV and STI testing, particularly for identifying asymptomatic infections, evaluating co-infections, and supporting clinical assessments involving pregnancy planning, fertility evaluation, and long-term reproductive health management. The findings also reinforce emerging scientific evidence suggesting that co-existing infections and alterations in the reproductive tract microbiome may influence HPV persistence, acquisition, and disease progression.
Global Million Clinical Study to Establish New PCR Testing Standards
Launched on July 8, 2026, the Global Million Clinical Study (GMCS) is designed to generate large-scale clinical evidence supporting disease-specific molecular diagnostic strategies across healthcare institutions worldwide. Through this initiative, Seegene plans to collect extensive real-world diagnostic data while evaluating the clinical utility, diagnostic accuracy, and medical applicability of comprehensive HPV and STI Syndromic PCR testing. By integrating results through the STAgora™ platform, the company intends to statistically validate how simultaneous pathogen detection may improve clinical decision-making compared with conventional single-pathogen testing approaches. The study represents one of Seegene’s most ambitious global research programs and reflects increasing demand for multiplex molecular diagnostics capable of identifying multiple infectious agents from a single patient specimen, improving both laboratory efficiency and patient care.
Advertisement
Syndromic PCR Expands Precision Diagnostics for Reproductive Health
Seegene believes its Syndromic PCR technology represents an important advancement in precision molecular diagnostics, enabling clinicians to detect multiple pathogens responsible for reproductive tract infections through a single comprehensive molecular assay. Because many STIs present with overlapping symptoms—or remain entirely asymptomatic—comprehensive pathogen identification can provide clinicians with more complete diagnostic information while supporting timely treatment decisions and improved infection control. The company plans to present additional scientific findings and the future direction of its HPV-STI comprehensive PCR testing strategy during the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Meeting in Anaheim, California. As healthcare systems increasingly adopt precision diagnostics, Seegene aims to establish comprehensive Syndromic PCR testing as a new global benchmark for reproductive health diagnostics, strengthening disease surveillance, improving patient outcomes, and advancing personalized clinical care.
Source: Seegene press release
